Septerna Inc. Common Stock (SEPN)

About SEPN

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric m…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

123

Website

septerna.com

Fundamentals

1-day range

$43.64$46.5

Market cap

$1.58B

P/E (trailing)

—

P/E (forward)

-24.33

EPS (trailing)

$-0.53

Dividend yield

—

Beta

—

Avg. volume

436.5K

Forecasts

9 analyst ratings

Septerna Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• SEPN

  Septerna Inc. Common Stock

  $38.91

  ▼ 3.85%
  Market cap $1.58BP/E —
  $10.74$51.1
• AAPG

  Ascentage Pharma Group International American Depository Shares

  $18.28

  ▼ 2.16%
  Market cap $1.57BP/E —
  $30$91.5
• TRAX

  First Tracks Biotherapeutics Inc. Ordinary Shares

  $41.77

  ▼ 6.64%
  Market cap $1.61BP/E —
  $14.72$49.91
• INVA

  Innoviva Inc. Common Stock

  $20.97

  ▲ 0.05%
  Market cap $1.53BP/E 4.21
  $16.52$25.15
• PAHC

  Phibro Animal Health Corporation Class A Common Stock

  $37.64

  ▲ 3.55%
  Market cap $1.51BP/E 14.51
  $28.25$60.08
• MRVI

  Maravai LifeSciences Holdings Inc. Class A Common Stock

  $7.67

  ▼ 8.42%
  Market cap $1.66BP/E —
  $2.28$9.42
• BCAX

  Bicara Therapeutics Inc. Common Stock

  $23.42

  ▼ 5.70%
  Market cap $1.69BP/E —
  $10.3$30.99

P/E shows — for peers not currently carrying a live signal of their own.

Institutional Ownership

March 31, 2026

Total shares held

45.33M

Total value held

$1.09B

Institutional holders

119